


Ondansetron



CAS

99614-02-5

Status

Commercial

[Inquiry](#)

Ondansetron is a drug that selectively acts as an agonist on 5-HT₃ receptors (serotonin receptors). If the cell death of serotonin-rich cells is triggered by radiotherapy or cytostatic therapy, the vomiting center is activated. Ondansetron blocks this reaction and can therefore be used as an antiemetic in tumor therapy. It is also effective in postoperative vomiting. The current data suggest that it also could be used for maternity sickness.

Description

Formula C₁₈H₁₉N₃O

Molecular weight 293.36 g/mol

Molecular size small

Controlled Substance no

Precursor no

Indications Antiemetics and antinauseants

Your Contact



Marius Hang

International Division

Director API Export

Midas Pharma GmbH

Rheinstr. 49

55218 Ingelheim

Germany

[Send E-Mail](#)

Disclaimer

The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.